APA (7th ed.) Citation

R, D., JF, B., ZC, J., YD, X., JJ, C., XL, Z., . . . GJ, T. (2026). Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma. Alimentary pharmacology & therapeutics, 63(12), 1617. https://doi.org/10.1111/apt.70612

Chicago Style (17th ed.) Citation

R, Ding, et al. "Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma." Alimentary Pharmacology & Therapeutics 63, no. 12 (2026): 1617. https://doi.org/10.1111/apt.70612.

MLA (9th ed.) Citation

R, Ding, et al. "Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma." Alimentary Pharmacology & Therapeutics, vol. 63, no. 12, 2026, p. 1617, https://doi.org/10.1111/apt.70612.